HiveProspectStranded Biotech Asset IntelligenceResearch intelligence
Research workspace tools

ezetimibe/simvastatin

TERMINATED · PHASE3 · Hyperlipidemia, Dyslipidemia

Unknown stopping reason

Registry source

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.